Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Phase II trial of panitumumab monotherapy for patients with KRAS exon2 wild type colorectal cancer after progression on cetuximab. HGCSG1101
Satoshi Yuki, Yoshimichi Komatsu, Toshiya Muranaka, Keisuke Harada, Junko Sugiyama, Yasushi Tsuji, Tsutomu Ando, A. Hosokawa, Kazuteru Hatanaka, Hirohito Naruse, Taro Takahata, Akiko Satô, Y. Kobayashi, T. Miyagishima, Hiroyuki Okuda, Masatoshi Kudo, Mitsuhiro Nakamura, Hiroyuki Hisai, Nobuaki Sakamoto, Yasushi Sakata (2016). Phase II trial of panitumumab monotherapy for patients with KRAS exon2 wild type colorectal cancer after progression on cetuximab. HGCSG1101. , 27, DOI: https://doi.org/10.1093/annonc/mdw370.45.
Article38 days agoP-269 Phase II trial of Irinotecan/S-1 (IRIS) with Cetuximab (IRIS/Cet) as second line treatment in patients with KRAS WT metastatic colorectal cancer: HGCSG0902. -Comparison of administration interval in Cetuximab treatment
Kazuteru Hatanaka, Satoshi Yuki, Hiroshi Nakatsumi, A. Hosokawa, Michio Nakamura, Osamu Muto, T. Meguro, Ichiro Iwanaga, Yasushi Tsuji, Akinori Sato, K. Eto, Koichi Furukawa, Makoto Onodera, M. Tateyama, Yasuo Takahashi, Masayoshi Dazai, Shigeyuki Yokoyama, Takuya Honda, Hiroyuki Okuda, Masatoshi Kudo, Yuh Sakata, Yoshito Komatsu (2015). P-269 Phase II trial of Irinotecan/S-1 (IRIS) with Cetuximab (IRIS/Cet) as second line treatment in patients with KRAS WT metastatic colorectal cancer: HGCSG0902. -Comparison of administration interval in Cetuximab treatment. , 26, DOI: https://doi.org/10.1093/annonc/mdv233.266.
Article38 days ago162P Updated analysis: Phase II trial of irinotecan plus S-1 (IRIS) with cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type metastatic colorectal cancer (mCRC): HGCSG0902
A. Hosokawa, Satoshi Yuki, Yasuyuki Kawamoto, Takayuki Ando, Osamu Muto, Michio Nakamura, Takashi Kato, Ichiro Iwanaga, Kazuteru Hatanaka, Yasushi Tsuji, Akinori Sato, K. Eto, Kouichi Furukawa, Hiroyuki Okuda, Hideo Hayashi, Kei Fujikawa, Masatoshi Kudo, Takuya Honda, Yuh Sakata, Yoshito Komatsu (2015). 162P Updated analysis: Phase II trial of irinotecan plus S-1 (IRIS) with cetuximab (IRIS/Cet) in pre-treated patients with KRAS wild type metastatic colorectal cancer (mCRC): HGCSG0902. , 26, DOI: https://doi.org/10.1093/annonc/mdv523.23.
Article38 days ago172P Updated analysis: observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin (OX) + BV and oral FU/OX + BV
Yoshito Komatsu, Satoshi Yuki, Hiroshi Nakatsumi, Kentaro Sawada, Kazuteru Hatanaka, Takashi Kato, T. Meguro, Michio Nakamura, Ichiro Iwanaga, Minoru Uebayashi, M. Tateyama, K. Eto, Masatoshi Kudo, K. Kato, Hiroyuki Okuda, Susumu Sogabe, T. Miyagishima, Kencho Miyashita, Naoya Sakamoto, Yuh Sakata (2015). 172P Updated analysis: observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin (OX) + BV and oral FU/OX + BV. , 26, DOI: https://doi.org/10.1093/annonc/mdv523.33.
Article38 days ago2092 Updated analysis: Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin(OX)+BV and oral FU/OX+BV
Hiroshi Nakatsumi, Satoshi Yuki, Yasuyuki Kawamoto, Toshiya Muranaka, Kazuteru Hatanaka, Takashi Kato, T. Meguro, Michio Nakamura, Ichiro Iwanaga, Minoru Uebayashi, M. Tateyama, Kojiro Eto, Masatoshi Kudo, Seiya Kato, Hiroyuki Okuda, Susumu Sogabe, Kencho Miyashita, Yuh Sakata, Naoya Sakamoto, Yoshihiko Komatsu (2015). 2092 Updated analysis: Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin(OX)+BV and oral FU/OX+BV. , 51, DOI: https://doi.org/10.1016/s0959-8049(16)31014-0.
Article38 days ago